Drug intelligence / Profile preview

rivanicline

Development stage: Preclinical
Lead developer: Targacept
Modality: Small Molecules
Administration: Oral

Overview

Rivanicline is a small molecule drug that acts as a partial agonist at neuronal nicotinic acetylcholine receptors, with selectivity for the α4β2 subtype. It was originally developed for its nootropic effects as a potential treatment for Alzheimer's disease. Subsequently, it was found to inhibit the production of Interleukin-8 (IL-8), conferring anti-inflammatory properties and leading to its development as an investigational therapy for ulcerative colitis. Rivanicline also exhibits stimulant and analgesic actions thought to be mediated by increased noradrenaline release. The compound has been evaluated in clinical trials up to phase II but development appears discontinued[1][2][3][4][5][6][7].

Other names: metanicotinerivanicline

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)

Beyond the preview

Go deeper on rivanicline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rivanicline.

Explore the full profile